Hexagon Capital Partners’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History
Bought
Maintained
Sold
Other funds holding LABD
HF
VF
JF
TRCT
TSS
Hexagon Capital Partners's LABD Position: Q1 2023 in Review
Hexagon Capital Partners sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2023, closing a stake of 13 shares — an estimated $2.16K sold.
Hexagon Capital Partners first reported a position in LABD in Q4 2022 and held it in 1 quarter. The position peaked at $2.16K in Q4 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2023.
- Hexagon Capital Partners reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2023 after selling out during the quarter.
- Hexagon Capital Partners sold 13 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2023, an estimated $2.16K.
- Hexagon Capital Partners first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2022 and held it in 1 quarter.
- Hexagon Capital Partners's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $2.16K in Q4 2022.
- 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2023.
Based on Hexagon Capital Partners's 13F filing for Q1 2023, filed 24 Apr 2023.